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ABSTRACT
BACKGROUND. Ap prox i mately 40% of all in di vid u als with ep i lepsy have med i cally re frac tory or in trac ta -
ble sei zures. Among the most com mon eti ol o gies are Mesiotemporal and tu ber ous scle ro sis, Sturge-Weber
syn drome, ce re bral tu mors, arteriovenous mal for ma tions, de vel op men tal mal for ma tions, and se quel of ce re -
bral in fec tions, in farcts or trauma. Levetiracetam (LEV) is a sec ond gen er a tion AED, in di cated as ad junc tive
ther apy in adults with par tial sei zures. OBJECTIVE. To as sess the ef fi cacy and safety of LEV add-on ther apy
in pa tients with struc tural brain le sions as so ci ated with med i cally re frac tory par tial ep i lepsy. MATERIAL
AND METHODS. Twelve pa tients (5 M and 7 F; aged 41.6 ±7.6 years) with tu mor and non-neo plas tic brain
le sions as so ci ated with re frac tory sei zures were in cluded in the study. Di ag no sis was based on the cri te ria of
ILAE. All pa tients had an ad junc tive ther apy with LEV (1000-3000 mg/daily) for at least six months. Drug ef -
fi cacy was as sessed as change in sei zure fre quency. Safety was as sessed as mea sure ment of re ten tion rate and
re port ing the drug re lated ad verse ef fects. Neuroimaging, EEG, and clin i cal fol low-up were per formed be fore 
and af ter ini ti a tion of LEV add-on ther apy. RESULTS. LEV add-on ther apy re duced sei zure fre quency in 85
per cent of pa tients and 46 per cent be came sei zure free. Re ten tion rate was 100 per cent for pa tients treated
with LEV. The most com mon side ef fect was tran sient som no lence, noted in 25 per cent of pa tients.
CONCLUSION. This study con firms the ef fi cacy and safety of LEV as add-on ther apy in pa tients with struc -
tural brain le sions. Due to its unique mech a nisms of ac tion, LEV pres ents a new ther a peu tic chal lenge even
for pa tients with highly re frac tory par tial ep i lepsy.
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INTRODUCTION
Mesiotemporal scle ro sis, tu ber ous scle ro sis, Sturge-Weber
syn drome, ce re bral tu mors, hamartoma, arteriovenous mal -
for ma tions, de vel op men tal mal for ma tions, and se quel of
ce re bral in fec tions, in farcts or trauma are the most com mon 
eti ol o gies that cause re frac tory sei zures (1,5,7,9,12). The
most fre quently pre scribed anticonvulsants of ten in ter act
with other med i ca tions, com pli cat ing their dos ing and di -
min ish ing their ef fec tive ness (7,8,13,15). Re cently, sig nif i -
cant ad vances in epileptology are re lated to the de vel op -
ment of new antiepileptic drugs (AEDs), as well as better
un der stand ing of their mech a nisms of ac tion and drug in -
ter ac tions (5,7,8,12,15). Levetiracetam (LEV) is a sec ond
gen er a tion AED, in di cated as ad junc tive ther apy in adults
with par tial sei zures (1,2,4,6,9,10,12,14). Be cause of its
unique mech a nism of ac tion (spe cif i cally re duces the
N-type high-volt age-ac ti vated Ca2+ cur rent and op poses
the ac tion of neg a tive mod u la tors of GABA and glycine re -
cep tors), it has been pos tu lated that LEV may be ef fec tive
in con trol ling brain le sion-in duced re frac tory sei zures
(1,2,3,11,14,15,16).
OBJECTIVE
To as sess the ef fi cacy and safety of LEV add-on ther apy in
pa tients with struc tural brain le sions as so ci ated with med i -
cally re frac tory par tial sei zures.
MATERIAL AND METHODS
Twelve pa tients (5 males and 7 fe males; aged 41.6 ±7.6years)
with struc tural brain le sions as so ci ated with re frac tory par tial
sei zures were in cluded in the study. Five (5) pa tients had brain
tu mors, 3 low-grade astrocytomas (Case 1) and 2 meningiomas. 
Seven (7) had non-neo plas tic brain le sions - 3 be nign arachnoid
cysts (Case 2), 2 ce re bral angiomas (Case 3), and 2 ce re bral
trauma with se quel (Case 4). They pre sented ei ther with sim ple
(70 per cent) or with com plex par tial (30 per cent) sei zures. Di ag -
no sis was based on the cri te ria of ILAE. All pa tients had an ad -
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junc tive ther apy with LEV (1000-2000 mg/daily) for at least six 
months. Drug ef fi cacy was as sessed as change in sei zure fre -
quency (per cent age of pa tients who be came sei zure free and
per cent age of pa tients who re sponded with >50% re duc tion in
sei zures). Safety was as sessed as mea sure ment of re ten tion rate
(per cent age of pa tients con tin u ing the treat ment) and re port ing
the drug re lated ad verse ef fects. Neuroimaging, EEG, and clin i -
cal fol low-up were per formed be fore and af ter ini ti a tion of LEV 
add-on ther apy.
CASE 1. A 56-years old fe male with low-grade glioma
who ex pe ri enced in creased sim ple par tial sei zures ac tiv ity
af ter sur gery was ad mit ted to the clinic. EEG find ings
showed left frontotemporal fo cus of ep i lep tic ac tiv ity. Post -
op er a tive CT scans dem on strated a re sid ual hypodense le -
sion and lack of tu mor re cur rence (Fig.1).
CASE 2. A 55-years old male was ad mit ted to the clinic
with med i cally re frac tory sim ple par tial sei zures. 
EEG dem on strated ep i lep tic fo cus in the left
frontotemporal re gion. CT scan showed a well-de fined,
non-en hanc ing hypodense le sion in the left frontotemporal
re gion (Fig.2).
CASE 3. A 25-years young male with SWS was ad mit ted
to the clinic with in creased fre quency of sec ond arily gen er -
al ized par tial sei zures. EEG re vealed a fo cus of ep i lep tic
ac tiv ity in the left tem po ral re gion. CT scans showed bi lat -
eral con trast en hanc ing hyperdense le sions in the tem po ral
and oc cip i tal re gions (Fig. 3).
CASE 4. A 17-years young male with fire-caused brain in -
jury was ad mit ted to the clinic with in creased fre quency of
com plex par tial sei zures 3 years af ter sur gery. EEG re -
vealed ep i lep tic ac tiv ity in both tem po ral re gions. Post op er -
a tive CT scans showed a re sid ual hypodense le sion with re -
sid ual pro jec tiles in the right fron tal re gion (Fig. 4). 
RESULTS
LEV add-on ther apy re duced sei zure fre quency in  85 per -
cent of pa tients. Over the treat ment pe riod 46 per cent of pa -
tients be came sei zure free. Drug ef fi cacy was higher in in -
di vid u als with non-neo plas tic brain le sions. Re ten tion rate
was 100 per cent for pa tients treated with LEV. The most
com mon side ef fect was tran sient som no lence, noted in 25
per cent of pa tients.
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Ap prox i mately 40% of all in di vid u als with ep i lepsy have
med i cally re frac tory sei zures (fail ure of two or more drugs
and oc cur rence of one or more sei zures per month over 18
months) that con tinue to oc cur de spite treat ment (5,13,16).
These ac quired in trac ta ble sei zures are most com mon in
pa tients with brain ma lig nan cies and non-neo plas tic ce re -
bral ab nor mal i ties (4,7,8,11,14,15). They of ten im pact on
pa tients' qual ity of life and sur vival. Clin i cal tri als and stud -
ies are sug ges tive that better un der stand ing of un der ly ing
pro cesses and bi o log i cal mech a nisms guar an tees the suc -
cess ful treat ment (5,8,10,12). Fur ther more, ev i dence ex ists
that all of the new AEDs dem on strate ef fi cacy as add-on
ther apy in pa tients with re frac tory sei zures (5,8,13,15). Ac -
cord ingly, Re port of the Amer i can Acad emy of Neu rol ogy
and the Amer i can Ep i lepsy So ci ety rec om mends us ing
LEV (Level A) in symp tom atic ep i lepsy as so ci ated with
sus pected or known struc tural brain le sions (7). Re spec -
tively, we stud ied a group of pa tients with pri mary brain tu -
mors or non-neo plas tic le sions and un con trolled sei zures.
Our re sults sup ported the pre vi ously re ported find ings that
LEV add-on ther apy re duces sei zure fre quency in most pa -
tients, with nearly 60 per cent be com ing sei zure free over
the treat ment pe riod (2,3,6,9,10,16). In cor re spon dence
with many ob ser va tions, som no lence was the most com -
mon side ef fect noted in our pa tients (1,2,4,14,15).
Re view of the lit er a ture re veals that multifactorial mech a -
nism of ep i lepsy is con sid ered in pa tients with dif fer ent
struc tural brain le sions (2,5,8,9,12,16). Based on our own
clin i cal, neuroimaging, and electrophysiological no tices,
we sup pose that the most likely are ce re bral edema and
ischemia, lo cal met a bolic im bal ances, changes in neuronal
and glial en zyme ex pres sion, and al tered im mu no log i cal
ac tiv ity.
CONCLUSION
In sum mary, the new antiepileptic drug LEV is in di cated as 
ad junc tive ther apy in the treat ment of par tial sei zures in
adults. Ac cord ingly, this study con firms its ef fi cacy and
safety as add-on ther apy in pa tients with struc tural brain le -
sions. We sug gest that, due to the unique mech a nisms of
ac tion, LEV pres ents a new ther a peu tic chal lenge even for
pa tients with highly re frac tory par tial ep i lepsy.
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